{"product_id":"revvity-al3066f","title":"Revvity, AL3066F, AlphaLISA Human LAG3 \/ MHC II (HLA-DR Subunit) Binding Kit, 5,000 Assay Points","description":"\u003cp\u003eOverview\u003cbr\u003e\nFeatures:\u003c\/p\u003e\n\n\u003cp\u003eNo-wash steps, no separation steps\u003cbr\u003e\nEase-of-use: few addition steps, fast assay development\u003cbr\u003e\nBroad range of affinities: detect strong or weak interactions, from pM to mM affinity\u003cbr\u003e\nDistance: measure very large protein or antibody complexes – spanning up to 200 nm or more\u003cbr\u003e\nHigh avidity: multiple binding sites on each bead enables use of nanomolar concentrations of antibodies or proteins, as well as use of low affinity binders\u003c\/p\u003e\n\n\u003cp\u003eAlphaLISA technology allows detecting the binding of target proteins in a highly sensitive, quantitative, reproducible and user-friendly mode. In this AlphaLISA assay, a biotinylated LAG-3 binds to the Streptavidin-coated Alpha Donor beads, while His-tagged HLA DRA is captured by Anti-His AlphaLISA Acceptor beads. When LAG-3 binding to HLA DRA happens, Donor beads and Acceptor beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.\u003cbr\u003e\nHuman Leukocyte Antigen (HLA) is an MHC (major histocompatibility complex) class II cell surface receptor. HLA DRA is one of Antigen D related HLA class II (HLA DR) alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Lymphocyte activation gene-3 (LAG-3), also known as CD223, is a member of the immunoglobulin superfamily. LAG-3 binds to MHC class II with higher affinity, providing negative regulation of T cell receptor signaling. Binding of a homodimerized LAG-3\/Ig fusion protein to MHC class II molecules induces maturation of immature dendritic cells and secretion of cytokines. Deletion of LAG-3 facilitates anti-cancer immune response, also blocks self-tolerance and increases susceptibility to autoimmune diseases. Because of its profound inhibitory role, blocking HLA DR and LAG-3 binding has been considered as promising therapeutic target for human autoimmune disease and cancers. \u003cbr\u003e\nApplication-Protein-Protein Interaction\u003cbr\u003e\nAutomation Compatible-Yes\u003cbr\u003e\nBrand-AlphaLISA\u003cbr\u003e\nDetection Modality-Alpha\u003cbr\u003e\nProduct Group-Kit\u003cbr\u003e\nSample Volume-5 µL\u003cbr\u003e\nShipping Conditions-Dual Temperature\u003cbr\u003e\nTarget-HLA-DRA, LAG3\u003cbr\u003e\nTarget Class-Binding Assay\u003cbr\u003e\nTarget Species-Human\u003cbr\u003e\nTechnology-Alpha\u003cbr\u003e\nTherapeutic Area-Immuno-oncology\u003cbr\u003e\nUnit Size-5,000 assay points\u003c\/p\u003e","brand":"Revvity","offers":[{"title":"Default Title","offer_id":46774539583657,"sku":"AL3066F","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/revvity-al3066f","provider":"Iright","version":"1.0","type":"link"}